25mg
Sponsors
Takeda Development Center Americas Inc., Sk Life Science Inc., Odense University Hospital, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
Attention-deficit/hyperactivity disorder (ADHD)Diabetic Neuropathy PeripheralPatients undergoing surgical aortic valve replacement.Primary Generalized Tonic-Clonic Seizures
Phase 1
Phase 3
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
RecruitingCTIS2023-506688-32-00
Start: 2019-10-09Target: 77Updated: 2025-12-10
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
CompletedCTIS2023-506687-13-00
Start: 2019-01-31End: 2025-05-26Target: 84Updated: 2025-04-02
Phase 4
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder
CompletedCTIS2022-502630-71-00
Start: 2019-11-20End: 2025-09-02Target: 68Updated: 2025-07-31
Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacement
and the influence of HMG-CoA reductase inhibitors
RecruitingCTIS2024-511601-34-00
Start: 2022-03-19Target: 366Updated: 2024-03-21